Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

Neuro-Oncology

Volumn 17, Issue 1, 2015, Pages 116-121

  Kaley, Thomas J ^a   Wen, Patrick ^b   Schiff, David ^c   Ligon, Keith ^b   Haidar, Sam ^b   Karimi, Sasan ^a   Lassman, Andrew B ^a,e   Nolan, Craig P ^a   De Angelis, Lisa M ^a   Gavrilovic, Igor ^a   Norden, Andrew ^b   Drappatz, Jan ^b   Lee, Eudocia Quant ^b   Purow, Benjamin ^c   Plotkin, Scott R ^d   Batchelor, Tracy ^d   Abrey, Lauren E ^a   Omuro, Antonio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Chemotherapy; Malignant meningioma; Sunitinib; Tyrosine kinase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; SUNITINIB; TUMOR MARKER; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN SCINTISCANNING; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COHORT ANALYSIS; CONFUSION; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EXPLORATORY RESEARCH; FEMALE; HAND FOOT SYNDROME; HEART RIGHT VENTRICLE HYPERTROPHY; HEMANGIOBLASTOMA; HEMANGIOPERICYTOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MALIGNANT MENINGIOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QT PROLONGATION; RECURRENCE RISK; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLEEDING; TUMOR DIFFERENTIATION; TUMOR EMBOLISM; TUMOR RECURRENCE; TUMOR THROMBUS; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MENINGEAL NEOPLASMS; MENINGIOMA; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 84922576713     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou148     Document Type: Article

References (36)

1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-oncology. 2013;15 Suppl 2:ii1-ii56.
2. Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol. 2010;99(3):365-378.
3. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012;107(2): 315-321.
4. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004; 62(7):1210-1212.
5. Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3): 271-276.
6. Swinnen LJ, Rankin C, Rushing EJ, et al. Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma (abstract #2063). J Clin Oncol. 2009;27:15s.
7. Grunberg SM, Rankin C, Townsend J, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clinical Oncol. 2001;20:56a. (Abstract 222).
8. Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75-77.
9. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74(6):861-866.
10. Johnson DR, Kimmel DW, Burch PA, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530-535.
11. Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40(2):271-275.
12. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63-70.
13. Markwalder TM, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomasa pilot study. Surg Neurol. 1985;24(3):245-249.
14. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012; 109(1):187-193.
15. Norden AD, Drappatz J,Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9(3):231-240.
16. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211-217.
17. Raizer JJ, Abrey LE, Lassman AB, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010;12(1):87-94.
18. Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012;106(2): 409-415.
19. Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortiumstudy 01-08). Neuro Oncol. 2009;11(6):853-860.
20. Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3(5):439-443.
21. Black PM, Carroll R, Glowacka D, et al. Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg. 1994;81(3):388-393.
22. Maxwell M, Galanopoulos T, Hedley-Whyte ET, et al. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer. 1990;46(1):16-21.
23. Nagashima G, Asai J, Suzuki R, et al. Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol. 2001;18(1): 1-5.
24. Wang JL, Nister M, Hermansson M, et al. Expression of PDGF beta-receptors in human meningioma cells. Int J Cancer. 1990; 46(5):772-778.
25. Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci. 2001; 8(Suppl 1):49-53.
26. Johnson MD, Woodard A, Kim P, et al. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg. 2001;94(2):293-300.
27. Todo T, Adams EF, Fahlbusch R, et al. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996;84(5):852-858; discussion 858-859.
28. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. 2000; 50(1-2):109-120.
29. Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathol. 2011; 28(2):99-106.
30. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
31. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
32. Mendel DB, Laird AD, Xin X,et al. Invivoanti tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337.
33. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
34. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45(2):131-132.
35. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45(2):180-185.
36. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125(5):651-658.